Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently Amended) A compound of formula I



I

in salt or zwitterionic form wherein

R^1 and R^3 are each independently a C_3-C_{15}-carbocyclic group or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur;

R^2 is ~~hydrogen,~~ hydroxy~~, or C_1-C_4-alkyl optionally substituted by hydroxy~~;

J is C_1-C_2-alkylene;

R^4 is C_1-C_4-alkyl;

R^5 is C_1-alkyl substituted by -CO-R^6, or -CO-NH-R^6,

or R^5 is C_2-C_{10}-alkyl substituted by -O-R^6, -O-CO-R^6, or -R^8,

or R^5 is C_2-C_{10}-alkenyl or C_2-C_{10}-alkynyl optionally substituted by -R^8;

R^6 is a C_3-C_{15}-carbocyclic group ~~or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur~~,

or R^6 is C_1-C_{10}-alkyl optionally substituted by C_1-C_{10}-alkoxy, -O-R^8 or a C_3-C_{15}-carbocyclic group ~~or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur~~; and

R^8 is a C_3-C_{15}-carbocyclic group.

Claim 2. (Canceled)

Claim 3. (Currently Amended) A compound according to claim 3 ~~claim 2~~, wherein

R^1 and R^3 are each independently a C_3-C_{10}-carbocyclic group, preferably phenyl, or a 5- to 9-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur, preferably thienyl;

R^2 is hydroxy;

J is C_1-C_2-alkylene;

R^4 is C_1-C_4-alkyl;

R^5 is C_1-alkyl substituted by -CO-R^6 or -CO-NH-R^6,

or R^5 is C_2-C_5-alkyl substituted by -O-R^6, -O-CO-R^6 or -R^8,

or R^5 is C_2-C_4-alkenyl or C_2-C_8-alkynyl optionally substituted by -R^8;
R^6 is a C_3-C_{10}-carbocyclic group, preferably phenyl,
or R^6 is C_1-C_{15}-alkyl optionally substituted by C_1-C_4-alkoxy, O-R^8 or a C_3-C_{10}-carbocyclic group; and
R^8 is a C_3-C_{10}-carbocyclic group, preferably phenyl.

Claims 4-7. (Canceled)

Claim 8. (Previously Presented): A compound according to claim 1, which is also a compound of formula XVI



XVI

where T is as shown in the following table:

T











Claim 9. (Previously Presented): A compound according to claim 1, which is also a compound of formula XVII



XVII

where T is as shown in the following table:

T








Claim 10. (Cancelled)

Claim 11. (Previously Presented): A pharmaceutical composition comprising as active ingredient a compound according to claim 1.

Claims 12-15. (Canceled)

Claim 16. (Currently Amended): A process for the preparation of a compound of formula I as claimed in claim 1 which comprises:

(i) (A) reacting a compound of formula II





or a protected form thereof where R^1, R^2, R^3, R^4, and J, are as defined in claim 1, with a compound of formula III

$$X—R^5 \qquad III$$

where R^5 is as defined in claim 1 and X is chloro, bromo or iodo;

(B) reacting a compound of formula IV





or a protected form thereof where R^1, R^2, R^3, R^5, <u>and</u> J<u>,</u> ~~L and M~~ are as defined in claim 1, with a compound of formula V

$$X—R^4 \qquad V$$

where R^4 is as defined in claim 1 and X is chloro, bromo or iodo; <u>and</u>

(ii) recovering the product in salt or zwitterionic form.

Claim 17. (Currently Amended): A compound of formula VI



VI

VI

in salt or zwitterionic form wherein

R^1 and R^3 are each independently a C_3-C_{15}-carbocyclic group or a 5- to 12-membered heterocyclic group having at least one ring heteroatom selected from nitrogen, oxygen and sulphur;

R^2 is ~~hydrogen,~~ hydroxy~~, or C_1-C_4-alkyl optionally substituted by hydroxy~~;

J is C_1-C_2-alkylene;

R^4 is C_1-C_4-alkyl; and

Q is C_1-C_{10}-alkylene.

Claim 18. (Original): A pharmaceutical composition according to claim 11 wherein the compound is a single enantiomer.

Claim 19. (Canceled)

Claim 20. (Withdrawn - Original): A method of treating a condition mediated by the muscarinic M3 receptor in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound of formula I as defined in claim 1 in free form or in the form of a pharmaceutically acceptable salt.

Claim 21. (Withdrawn - Original): A method of treating an inflammatory or obstructive airways disease in a subject in need of such treatment, which comprises administering to said subject an effective amount of a compound of formula I as defined in claim 1 in free form or in the form of a pharmaceutically acceptable salt.

Claim 22. (Withdrawn - Original): A method according to claim 20, in which the compound of formula I is a single enantiomer.